Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders

ObjectivesThe primary objective of this project was to explore the challenges related to the implementation of patient-reported outcome measures (PROMs) in myeloma, lymphoma and leukaemia patients undergoing chimeric antigen receptor T-cell (CAR-T) and T Cell engager bispecific antibody (BsAbs) ther...

Description complète

Détails bibliographiques

Auteurs principaux:	Eilidh M Duncan, Jhulia Salviano, Charalampia Kyriakou, Samantha Nier, Simone Oerlemans, Sam Salek, Kate Morgan, Katie Joyner
Format:	Artigo
Langue:	Inglês
Publié:	Frontiers Media S.A. 2026-05-01
Collection:	Frontiers in Hematology
Sujets:	bispecific antibodies chimeric antigen receptor T-cell therapy (CAR-T) clinical trials haematological malignancies patient-reported outcome measures (PROM) patient-reported outcomes (PRO)
Accès en ligne:	https://www.frontiersin.org/articles/10.3389/frhem.2026.1800304/full
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!